About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 108 record(s)
Req # A-2022-000445
All records that discuss a delay in critical cancer diagnoses, treatment or similar as a direct consequence of COVID-19.Organization: Health Canada
January 2023
Req # A-2022-000516
Access to information request for the following companies: Medego Immobilier Inc. (NEQ: 1167724245) 12 De Richelieu Street, Chambly, Quebec, J3L 2B9, Chirurgie Dix30 Inc. (NEQ: 1169096287) 220-9090 Leduc Blvd., Brossard, Quebec, J4Y 0E2. As part of due diligence on the above-mentioned companies, we would like certain information regarding the status of these companies' records with your organization.Organization: Health Canada
January 2023
Req # A-2022-000524
All emails regarding the Subway comments after the All Staff meeting, as well as all the follow-up emails regarding the Subway comments, as well as all emails regarding the memes and comments being circulated since the All Staff meeting.Organization: Health Canada
January 2023
Req # A-2022-000855
The initial cover letters or any other document for all Abbreviated New Drug Submissions (ANDS) indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-08-11 for the medicinal ingredient rivaroxaban. The Screening Acceptance Letters for all ANDS from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for rivaroxaban which appear in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-08-11."Organization: Health Canada
January 2023
Req # A-2022-000907
Records generated from Jan 1, 2008 and Jan 1, 2022, regarding the amount of deaths per year in Canada due to lung cancer. Statistics and data, along with any information explaining the patient’s history. Statistics on if radon was listed as a cause for the cancer.Organization: Health Canada
January 2023
Req # A-2022-000952
Information about the monitoring you do for the use of Trampolines. Results of your monitoring. Actions you do to prevent injuries. Your plan to limit the use for children.Organization: Health Canada
January 2023
Req # A-2022-000975
As part of due diligence on the above-mentioned company (hereafter the "Company"), we would like certain information regarding the status of this company's records with your organization. Company: 9385-6599 Québec inc. (NEQ: 1174006024) Address: 22 Saint-Charles Street, Sainte-Thérèse, Quebec, J7E 2A4.Organization: Health Canada
January 2023
Req # A-2022-000988
All letters written to Health Canada by the public regarding or relating to Joyce Echaquan and her death, including but not limited to letters addressed to the Minister of Health, Deputy Minister of Health, Associate Ministers of Health, and Director General. Please provide a timeline including dates when letters were receivedOrganization: Health Canada
January 2023
Req # A-2022-000991
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-10-20 for the medicinal ingredient bupivacaine hydrochloride. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for bupivacaine hydrochloride which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-10-20.Organization: Health Canada
January 2023
Req # A-2022-000995
The initial cover letters indicating the sponsors for all of the Abbreviated New Drug Submission (ANDS), the brand name of the reference drug production each ANDS and the dosage form of the generic drugs in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-10-20 for the medicinal ingredient sugammadex sodium. The Screening Acceptance Letter from Health Canada to all the generic drug manufacturers confirming completion of screening of the ANDS for sugammadex sodium which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-10-20.Organization: Health Canada
January 2023